EATRIS-CONNECT
|
|
EATRIS-CONNECT
|
|
prof. dr. Irena Mlinarič-Raščan
|
|
HORIZON-RIA
|
|
01. 05. 2024 - 30. 04. 2027
|
Degradation of CDK1 and HDACs as a strategy to treat T-cell malignancies
|
|
CELSA/23/038 |
|
Izr. prof. dr. Izidor Sosič
|
|
CELSA
|
|
01. 10. 2023 - 30. 09. 2025
|
Exploiting structural insights in IP3 receptor function to develop novel, allosteric
inhibitors of IP3 receptor channels (SINFONIC)
|
|
CELSA/23/031
|
|
Prof. dr. Tihomir Tomašič
|
|
CELSA
|
|
01. 10. 2023 - 30. 09. 2025
|
A training network on the design of precision therapeutics that target key glycan motifs implicated in cancer
|
|
GlyCanDrug
|
|
Prof. dr. Marko Anderluh
|
|
Horizon Europe
|
|
01. 12. 2023 – 30. 11. 2027
|
Protein degraders for targeting galectin-8
|
|
PROTAG - 8
|
|
Prof. dr. Marko Anderluh
|
|
Horizon Europe
|
|
01. 09. 2024 – 31. 08. 2026
|
The role of snoRNAs in the etiology of inflammatory bowel disease
|
|
CELSA/22/026
|
|
Izr. prof. dr. Tomaž Bratkovič
|
|
CELSA
|
|
01. 10. 2022 - 30. 09. 2024
|
Razvoj raziskovalne infrastrukture za mednarodno konkurenčnost slovenskega RRI prostora
|
|
|
|
Prof. dr. Irena Mlinarič-Raščan
|
|
EATRIS ERIC
|
|
2021 - 2030
|
Digital Osce for Medical specialities - INnOvatlon for Students
|
|
DOMINOS
|
|
Prof. dr. Mitja Kos
|
|
ERASMUS+
|
|
01. 01.02022 - 31. 12. 2024
|
EATRIS-Plus – flagship in personalized medicine
|
|
EATRIS Plus
|
|
Prof. dr. Irena Mlinarič-Raščan
|
|
H2020
|
|
01. 01. 2020 - 31. 12. 2023
|
REMEDI4ALL
|
|
REMEDI4ALL
|
|
Prof. dr. Irena Mlinarič-Raščan
|
|
Horizon Europe
|
|
01. 09. 2021 - 31. 08. 2027
|
European Partnership for the Assessment of Risks from Chemicals (PARC)
|
|
PARC
|
|
Prof. dr. Marija Sollner Dolenc
|
|
Horizon Europe
|
|
01. 05. 2022 - 30. 04. 2029
|
Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria through existing antibiotics by making their outer membrane permeable
|
|
BREAKthrough
|
|
prof. dr. Stanislav Gobec
|
|
Horizon Europe
|
|
01. 01. 2023 – 31. 12. 2026
|
| Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology |
|
SIMPATIC |
|
Prof. dr. Rok Dreu |
|
Horizon Europe |
|
01. 07. 2023 – 30. 06. 2028 |